The BIOSECURE Act is expected to be included in a legislative package before the end of the year, and legal experts on the generic drug industry are warning that the bill, which aims to cut off federal contracting with biotech companies tied to adversarial countries, will be costly, technically complex and likely lead to more drug shortages. Politico reported this week that, according to an aide, House Speaker Mike Johnson (R-LA) will push for inclusion of BIOSECURE in the...